JP2009511519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511519A5 JP2009511519A5 JP2008534910A JP2008534910A JP2009511519A5 JP 2009511519 A5 JP2009511519 A5 JP 2009511519A5 JP 2008534910 A JP2008534910 A JP 2008534910A JP 2008534910 A JP2008534910 A JP 2008534910A JP 2009511519 A5 JP2009511519 A5 JP 2009511519A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- condition
- compound
- disorder
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- JESCETIFNOFKEU-SJORKVTESA-N (2s,5r)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide Chemical compound N1[C@H](C(=O)N)CC[C@@H]1C(C=C1)=CC=C1OCC1=CC=CC=C1F JESCETIFNOFKEU-SJORKVTESA-N 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000028505 alcohol-related disease Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- JESCETIFNOFKEU-DJNXLDHESA-N (2s)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide Chemical compound N1[C@H](C(=O)N)CCC1C(C=C1)=CC=C1OCC1=CC=CC=C1F JESCETIFNOFKEU-DJNXLDHESA-N 0.000 claims 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520581A GB0520581D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0520581.0 | 2005-10-10 | ||
| GB0523045.3 | 2005-11-11 | ||
| GB0523045A GB0523045D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603900.2 | 2006-02-27 | ||
| GB0603900A GB0603900D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0618336A GB0618336D0 (en) | 2006-09-18 | 2006-09-18 | Novel compounds |
| GB0618336.2 | 2006-09-18 | ||
| PCT/EP2006/009731 WO2007042239A1 (en) | 2005-10-10 | 2006-10-06 | Prolinamide derivatives as sodium channel modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009511519A JP2009511519A (ja) | 2009-03-19 |
| JP2009511519A5 true JP2009511519A5 (https=) | 2009-11-26 |
| JP5139305B2 JP5139305B2 (ja) | 2013-02-06 |
Family
ID=37546777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534910A Expired - Fee Related JP5139305B2 (ja) | 2005-10-10 | 2006-10-06 | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7655693B2 (https=) |
| EP (1) | EP1934177B8 (https=) |
| JP (1) | JP5139305B2 (https=) |
| KR (1) | KR101282464B1 (https=) |
| AR (1) | AR056575A1 (https=) |
| AT (1) | ATE556049T1 (https=) |
| AU (1) | AU2006301470B2 (https=) |
| BR (1) | BRPI0616944B8 (https=) |
| CA (1) | CA2625642C (https=) |
| CR (1) | CR9898A (https=) |
| EA (1) | EA015736B1 (https=) |
| ES (1) | ES2387405T3 (https=) |
| IL (1) | IL192627A0 (https=) |
| MA (1) | MA29817B1 (https=) |
| NO (1) | NO20082145L (https=) |
| NZ (1) | NZ567051A (https=) |
| PE (1) | PE20070592A1 (https=) |
| PL (1) | PL1934177T3 (https=) |
| TW (1) | TW200730494A (https=) |
| WO (1) | WO2007042239A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143306B2 (en) * | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| WO2011015537A1 (en) * | 2009-08-05 | 2011-02-10 | Glaxo Group Limited | Co-therapy for the treatment of epilepsy and related disorders |
| JP5855000B2 (ja) * | 2009-09-14 | 2016-02-09 | クオンベルゲンセ プハルマセウトイカルス リミテッド | α−カルボキサミド誘導体の製造方法 |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| EP3110794A1 (en) | 2014-02-27 | 2017-01-04 | Merck Patent GmbH | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| ES2912881T3 (es) * | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| JP2019537601A (ja) * | 2016-11-02 | 2019-12-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 新規投薬レジメン |
| MX2019013758A (es) * | 2017-05-19 | 2020-07-20 | Biogen Ma Inc | Formas cristalinas novedosas. |
| CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| CA3077088A1 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | Process for preparing spiro derivatives |
| KR20210002472A (ko) * | 2018-04-16 | 2021-01-08 | 바이오젠 엠에이 인코포레이티드 | 신경병증성 통증을 치료하는 방법 |
| MX2021012421A (es) * | 2019-04-10 | 2022-02-10 | Biogen Inc | Procesos para preparar derivados de pirrolidina alfa-carboxamida. |
| AU2020271856A1 (en) * | 2019-04-10 | 2021-12-02 | Biogen Ma Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| US12544385B2 (en) | 2020-01-30 | 2026-02-10 | Mohammad JAVED | Combination drug therapies for CNS disorders |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| US6136131A (en) * | 1998-06-02 | 2000-10-24 | Instrument Specialties Company, Inc. | Method of shielding and obtaining access to a component on a printed circuit board |
| CA2368631A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| MY134480A (en) | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
| EP1618099A4 (en) | 2003-04-18 | 2008-07-16 | Merck & Co Inc | BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| WO2005100334A1 (en) | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
| EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| US7858786B2 (en) | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| WO2006124865A2 (en) | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| EP1928886B1 (en) | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136986A patent/TW200730494A/zh unknown
- 2006-10-06 EP EP06806110A patent/EP1934177B8/en active Active
- 2006-10-06 NZ NZ567051A patent/NZ567051A/en unknown
- 2006-10-06 WO PCT/EP2006/009731 patent/WO2007042239A1/en not_active Ceased
- 2006-10-06 AT AT06806110T patent/ATE556049T1/de active
- 2006-10-06 AU AU2006301470A patent/AU2006301470B2/en not_active Ceased
- 2006-10-06 PL PL06806110T patent/PL1934177T3/pl unknown
- 2006-10-06 ES ES06806110T patent/ES2387405T3/es active Active
- 2006-10-06 BR BRPI0616944A patent/BRPI0616944B8/pt not_active IP Right Cessation
- 2006-10-06 JP JP2008534910A patent/JP5139305B2/ja not_active Expired - Fee Related
- 2006-10-06 KR KR1020087011271A patent/KR101282464B1/ko not_active Expired - Fee Related
- 2006-10-06 US US11/570,560 patent/US7655693B2/en active Active
- 2006-10-06 PE PE2006001225A patent/PE20070592A1/es not_active Application Discontinuation
- 2006-10-06 CA CA2625642A patent/CA2625642C/en active Active
- 2006-10-06 EA EA200801054A patent/EA015736B1/ru not_active IP Right Cessation
- 2006-10-09 AR ARP060104441A patent/AR056575A1/es not_active Application Discontinuation
-
2008
- 2008-03-31 MA MA30797A patent/MA29817B1/fr unknown
- 2008-04-18 CR CR9898A patent/CR9898A/es not_active Application Discontinuation
- 2008-05-07 NO NO20082145A patent/NO20082145L/no not_active Application Discontinuation
- 2008-07-03 IL IL192627A patent/IL192627A0/en active IP Right Grant
-
2009
- 2009-12-17 US US12/641,111 patent/US8153681B2/en not_active Expired - Fee Related